These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 20800424

  • 1. Novel aspects of in vitro IL-2 or IFN-α enhanced NK cytotoxicity of healthy individuals based on NKG2D and CD161 NK cell receptor induction.
    Konjević G, Mirjačić Martinović K, Vuletić A, Radenković S.
    Biomed Pharmacother; 2010 Dec; 64(10):663-71. PubMed ID: 20800424
    [Abstract] [Full Text] [Related]

  • 2. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.
    Konjević G, Mirjačić Martinović K, Vuletić A, Babović N.
    Melanoma Res; 2010 Dec; 20(6):459-67. PubMed ID: 20938360
    [Abstract] [Full Text] [Related]

  • 3. In vitro increased natural killer cell activity of metastatic melanoma patients with interferon-α alone as opposed to its combination with 13-cis retinoic acid is associated with modulation of NKG2D and CD161 activating receptor expression.
    Konjevic G, Mirjacic-Martinovic K, Vuletic A, Babovic N.
    J BUON; 2012 Dec; 17(4):761-9. PubMed ID: 23335538
    [Abstract] [Full Text] [Related]

  • 4. Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells.
    Konjević G, Mirjacić Martinović K, Jurisić V, Babović N, Spuzić I.
    Biomarkers; 2009 Jun; 14(4):258-70. PubMed ID: 19489688
    [Abstract] [Full Text] [Related]

  • 5. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.
    Huenecke S, Zimmermann SY, Kloess S, Esser R, Brinkmann A, Tramsen L, Koenig M, Erben S, Seidl C, Tonn T, Eggert A, Schramm A, Bader P, Klingebiel T, Lehrnbecher T, Passweg JR, Soerensen J, Schwabe D, Koehl U.
    J Immunother; 2010 Jun; 33(2):200-10. PubMed ID: 20145545
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.
    Decot V, Voillard L, Latger-Cannard V, Aissi-Rothé L, Perrier P, Stoltz JF, Bensoussan D.
    Exp Hematol; 2010 May; 38(5):351-62. PubMed ID: 20172016
    [Abstract] [Full Text] [Related]

  • 8. [Immunoediting of natural killer cells by human nasopharyngeal carcinoma cell line: altered expression of KIRs and NKG2D receptors leads to reduction of natural killer cell-mediated cytolysis].
    Guo KY, Mei JZ, Yao KT.
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):247-9. PubMed ID: 17425963
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Expression of killer immunoglobulin-like receptors on peripheral blood NK cell subsets of women with recurrent spontaneous abortions or implantation failures.
    Ntrivalas EI, Bowser CR, Kwak-Kim J, Beaman KD, Gilman-Sachs A.
    Am J Reprod Immunol; 2005 May; 53(5):215-21. PubMed ID: 15833099
    [Abstract] [Full Text] [Related]

  • 11. Telomere length in human natural killer cell subsets.
    Ouyang Q, Baerlocher G, Vulto I, Lansdorp PM.
    Ann N Y Acad Sci; 2007 Jun; 1106():240-52. PubMed ID: 17303822
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
    Kim JY, Bae JH, Lee SH, Lee EY, Chung BS, Kim SH, Kang CD.
    J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.